These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1090 related items for PubMed ID: 30197098

  • 1. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
    Fizazi K, Smith MR, Tombal B.
    Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
    [Abstract] [Full Text] [Related]

  • 2. Darolutamide (ODM-201) for the treatment of prostate cancer.
    Shore ND.
    Expert Opin Pharmacother; 2017 Jun; 18(9):945-952. PubMed ID: 28490267
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study.
    Saad F, Hussain MHA, Tombal B, Fizazi K, Sternberg CN, Crawford ED, Nordquist LT, Bögemann M, Tutrone R, Shore ND, Belkoff L, Fralich T, Jhaveri J, Srinivasan S, Li R, Verholen F, Kuss I, Smith MR.
    Eur Urol; 2024 Oct; 86(4):329-339. PubMed ID: 38644146
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
    Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR, ARAMIS Investigators.
    N Engl J Med; 2020 Sep 10; 383(11):1040-1049. PubMed ID: 32905676
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial.
    Shore N, Zurth C, Fricke R, Gieschen H, Graudenz K, Koskinen M, Ploeger B, Moss J, Prien O, Borghesi G, Petrenciuc O, Tammela TL, Kuss I, Verholen F, Smith MR, Fizazi K.
    Target Oncol; 2019 Oct 10; 14(5):527-539. PubMed ID: 31571095
    [Abstract] [Full Text] [Related]

  • 11. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
    Chung C, Abboud K.
    Am J Health Syst Pharm; 2022 Jul 22; 79(15):1224-1235. PubMed ID: 35390118
    [Abstract] [Full Text] [Related]

  • 12. Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis.
    Carles J, Medina-Lopez RA, Puente J, Gómez-Ferrer Á, Nebra JC, Sáez Medina MI, Ribal MJ, Antolín AR, Álvarez-Ossorio JL, Suárez Novo JF, Agut CM, Srinivasan S, Ortiz J, Fizazi K.
    Future Oncol; 2023 Apr 22; 19(12):819-828. PubMed ID: 37222151
    [Abstract] [Full Text] [Related]

  • 13. Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.
    Scott LJ.
    Target Oncol; 2020 Dec 22; 15(6):791-799. PubMed ID: 33237495
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer.
    Fizazi K, Albiges L, Loriot Y, Massard C.
    Expert Rev Anticancer Ther; 2015 Dec 22; 15(9):1007-17. PubMed ID: 26313416
    [Abstract] [Full Text] [Related]

  • 20. Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.
    Shore ND, Gratzke C, Feyerabend S, Werbrouck P, Carles J, Vjaters E, Tammela TLJ, Morris D, Aragon-Ching JB, Concepcion RS, Emmenegger U, Fleshner N, Grabbert M, Lietuvietis V, Mahammedi H, Cruz FM, Paula A, Pieczonka C, Rannikko A, Richardet M, Silveira G, Kuss I, Le Berre MA, Verholen F, Sarapohja T, Smith MR, Fizazi K.
    Oncologist; 2024 Jul 05; 29(7):581-588. PubMed ID: 38394384
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.